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Aim: This article discusses the current use of volumetric modulated arc therapy (VMAT) 
techniques in clinical practice and reviews the available data from clinical outcome studies 
in different clinical settings. An overview of available literature about clinical outcomes with 
VMAT stereotactic/radiosurgical treatment is also reported.
Materials and methods: All published manuscripts reporting the use of VMAT in a clinical 
setting from 2009 to November 2016 were identified. The search was carried out in December 
2016 using the National Library of Medicine (PubMed/Medline). The following words were 
searched: “volumetric arc therapy”[All Fields] OR “vmat”[All Fields] OR “rapidarc”[All Fields], 
AND “radiotherapy”[All Fields] AND “Clinical Trial”[All Fields].
Results: Overall, 37 studies (21 prospective and 16 retrospective) fulfilling inclusion criteria 
and thus included in the review evaluated 2,029 patients treated with VMAT; of these 
patients, ~30.8% had genitourinary (GU) tumors (81% prostate, 19% endometrial), 26.2% 
head-and-neck cancer (H&NC), 13.9% oligometastases, 11.2% had anorectal cancer, 10.6% 
thoracic neoplasms (81% breast, 19% lung), and 7.0% brain metastases (BMs). Six different 
clinical scenarios for VMAT use were identified: 1) BMs, 2) H&NC, 3) thoracic neoplasms, 
4) GU cancer, 5) anorectal tumor, and 6) stereotactic body radiation therapy (SBRT) performed 
by VMAT technique in the oligometastatic patient setting.
Conclusion: The literature addressing the clinical appropriateness of VMAT is scarce. Current 
literature suggests that VMAT, especially when used as simultaneous integrated boost or SBRT 
strategy, is an effective safe modality for all cancer types.
Keywords: VMAT, RapidArc, clinical trial, review, radiosurgery, stereotactic, simultaneous 
integrated boost
Introduction
Since the introduction of intensity-modulated radiotherapy (IMRT) in clinical routine 
in the late 1990s, a very fast growth has characterized radiotherapy (RT) technology 
offering newer technologies and techniques to radiation oncologists. Indeed, IMRT,1 
helical tomotherapy,2 intensity-modulated arc therapy (IMAT),3 and volumetric modu-
lated arc therapy (VMAT)4 enable better radiation dose conformality to the target 
volume compared to three-dimensional conformal radiotherapy (3D-CRT).
Moreover, these techniques, which underlie various complex computer-based optimi-
zation algorithms, allowed the delivery of nonuniform radiation beam intensities in order 
to obtain highly conformal dose distributions, thus potentially resulting in RT dose escala-
tion to the target with an improved cancer control. Moreover, they allowed the delivery of 
simultaneous integrated boost (SIB), a technique that permits treating of several volumes 
safely with different dose prescriptions, thus leading to reduction of the dose to the sur-
rounding radiation-sensitive normal tissues and improvement of the toxicity profile.
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In this context, VMAT represents the newest RT 
technique and can provide additional advantages, such as 
reduced treatment delivery time compared with conventional 
static field IMRT. In fact, in VMAT delivery, field shapes, 
dose rate, and gantry rotation speed can simultaneously 
vary. These additional degrees of freedom increased the 
capability of beam intensity modulation with respect to 
IMAT. Based on Otto’s VMAT algorithm,4 Varian (Palo 
Alto, CA, USA) implemented the single-arc form of IMAT 
and named the system RapidArcTM®. Elekta (Stockholm, 
Sweden) and Philips (Amsterdam, the Netherlands) also 
released their rotational IMRT solutions, named VMAT® 
and SmartArcTM®, respectively. Since the clinical imple-
mentation of these different rotational forms of IMRT by 
different vendors, the feasibility of applying this novel 
delivery technique to different cancer sites has been widely 
explored. Theoretical investigation and a very large number 
of treatment planning studies have extensively addressed 
the differences among VMAT, 3D-CRT, IMRT, and helical 
tomotherapy.5–15
In the last decade, technological improvements in setup, 
imaging, accuracy in dose delivery, and the ability to com-
pensate for respiratory motion have led to a widespread 
clinical implementation of stereotactic body radiation therapy 
(SBRT), also named as stereotactic ablative radiotherapy 
(SABR). SBRT refers to the delivery of large focused doses 
over a limited number of fractions to tumor sites, in order to 
obtain the highest biological effective dose. Because of its 
rotational nature and its fast delivery timing, VMAT has been 
immediately recognized as an ideal technique for SBRT that 
requires steep dose gradients, high precision, and reduction of 
treatment time, thus minimizing the risk of intrafraction setup 
deviations or organ motion.16 In this context, a few dosimetric 
and feasibility studies have confirmed high-dose conformity 
and fast delivery time in several types of malignancies.17–23
The clinical worldwide use of VMAT is significantly 
increasing; despite that, the majority of published data are 
currently confined to planning and feasibility studies.5–15 
Results relative to toxicity and clinical outcome are emerging, 
but still sparse.
This article aims to discuss the current use of VMAT 
techniques in clinical practice and review the available data 
from clinical outcome studies in different clinical settings 
including brain metastases (BMs), head and neck primary 
neoplasms, thoracic tumors, lower gastrointestinal (GI), 
and genitourinary (GU) cancers. Moreover, an overview of 
the available literature about clinical outcomes with VMAT 
stereotactic/radiosurgical treatment is reported.
Materials and methods
Search strategy
All published manuscripts reporting the use of VMAT in a 
clinical setting from 2009 (ie, 1 year after VMAT technique 
implementation) to November 2016 were identified. The 
search was carried out in December 2016 using the National 
Library of Medicine (PubMed/Medline). The following 
words were searched: “volumetric arc therapy”[All Fields] 
OR “vmat”[All Fields] OR “rapidarc”[All Fields], AND 
“radiotherapy”[All Fields] AND “Clinical Trial”[All Fields]. 
In order to identify other possible studies of interest, this 
process was supplemented by manual examination of ref-
erence lists for the available review articles24,25 or clinical 
trial papers.
Selection criteria
Eligible studies met the following criteria: published paper 
investigating an adult population with any cancer treated with 
VMAT, regardless of clinical indication or setting (ie, exclu-
sive, neoadjuvant, adjuvant, and palliative). Additional 
inclusion criteria were studies, 1) with oncological or toxicity 
outcomes from VMAT, and 2) published in the English 
language. Excluded publications were, 1) dosimetric or fea-
sibility studies without clinical data; 2) reviews, editorials, 
case reports, conference abstracts, and letters to editor; 
3) repeated publications by the same institution (ie, analysis 
was restricted to the most recent or the most comprehensive 
one); 4) papers reporting comparison between techniques 
from which it was not possible to extract and separately 
evaluate the outcome data of 1 arm over the other.
The title, abstract, and keywords of the identified articles 
were independently analyzed by a pool of researchers 
(GS, MF, SC, and AG) and disagreement was resolved by 
2 supervisors’ opinions (GM and FD); thereafter, papers not 
suitable for analysis were excluded as mutually agreed.
Potentially eligible studies were retrieved and a full-text 
evaluation was performed as to whether they satisfied the 
inclusion and exclusion criteria.
Data collection and analysis
The following data were collected by at least 2 researchers: 
author’s name and year of publication, study design, clinical 
setting, number of treated patients, tumor site, VMAT dose, 
fractionation and technique, image guidance (IG) availability, 
acute and late toxicity, follow-up time, clinical finding, local 
control, disease-free survival (DFS), and overall survival (OS). 
A descriptive analysis was used for the data report. The results 
are stratified by anatomic site to aid in the interpretation.
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Results
According to the search strategy, we were able to identify 
116 citations, 97 identified through database searching and 
19 identified through other sources (review articles). Based on 
the title and abstract, 72 publications were excluded because 
they involved dosimetric issues (n=62), or irrelevant topics 
(n=10), leading to 42 full-text articles selected for full inspec-
tion. Subsequently, 7 papers were excluded since they reported 
subset analyses of already selected papers, a case series, and 
an early halted trial, thus leaving 37 studies (21 prospective 
and 16 retrospective) fulfilling inclusion criteria and therefore 
included in the final review (Figure 1).
Overall, these studies evaluated 2,029 patients treated with 
VMAT; of these patients, ~30.8% had GU tumors (81% pros-
tate, 19% endometrial), 26.2% head-and-neck cancer (H&NC), 
13.9% oligometastases, 11.2% anorectal cancer, 10.6% tho-
racic neoplasms (81% breast, 19% lung), and 7.0% BMs.
Six different clinical scenarios for VMAT use were 
identified: 1) BMs, 2) H&NC, 3) thoracic neoplasms, 4) GU 
cancer, 5) anorectal tumor, and 6) SBRT performed by 
VMAT technique in the oligometastatic patient setting.
For the sake of clarity, we will present and discuss data, 
site by site.
BMs: exclusive, adjuvant, and prophylactic 
settings
BMs are the most common brain tumors in adults and occur 
in 20%–40% of patients with cancer;26 BMs often cause 
morbidity and mortality because of effect of the mass or brain 
site-related symptoms.27–29 The use of a sophisticated technique, 
such as the VMAT, in this setting is driven by the aim of 
reducing the irradiation of healthy brain, potentially allowing 
dose escalation (Table 1).30–33 In this context, 3 studies have 
investigated the clinical efficacy of VMAT–SIB in different 
clinical settings including exclusive treatment in the vast major-
ity of cases.30–32 It has to be acknowledged that the VMAT–SIB 
approaches diverged in terms of total dose, dose per fraction, 
and timing, thus sustaining a different toxicity profile. In 
particular, the use of high dose per fraction resulted in higher 
radionecrosis.32 Overall, the available studies confirmed that 
BMs can be successfully managed with a satisfying clini-
cal outcome; indeed, despite the heterogeneity of follow-up 
length as well as clinical end points, the rate of local control 
was ~80%. In this context, the optimization of the therapeutic 
window is clinically relevant since the rate of impairment of 
neurocognitive functions is not negligible32 and, more impor-
tantly, leads to a large amount of social and family sequelae. 
Prospective assessment of neurocognitive functions before and 
after hippocampus-sparing whole-brain radiotherapy (WBRT) 
has shown that adherence to the reference constraints guar-
antees preservation of neuro-cognitive functions and verbal 
memory.33 The only caveat remains the deep brain metastases 
(basal ganglia and thalamus) where the risk of radionecrosis 
resulted unacceptable at the suggested doses.32
H&NC: exclusive and adjuvant settings
H&NC accounts for 6% of all malignancies, and almost half 
of patients present with a locally advanced stage due to an 
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Figure 1 Flow chart – study selection diagram.
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aggressive phenotype and rapid growth because of the rich 
lymphatic supply of this region.34 RT for H&NC can be 
challenging due to the complex anatomy, with tumors often 
located within close proximity to critical structures (spinal 
cord, salivary glands, eyes, and dysphagia-related structures) 
which can limit radiation dose. RT is an important treatment 
modality in these tumors as it offers an alternative treatment 
option to surgical resection which can cause unacceptable 
cosmetic disfigurement and functional impairment.35,36 In the 
last decade, IMRT has gradually assumed an important role in 
the management of such diseases because it enables delivery 
of highly conformal dose distributions and increases the ther-
apeutic ratio as target volumes are often large and concave 
around nearby critical normal tissues.37–39 As shown in the 
randomized PARSPORT trial (ISRCTN48243537), IMRT 
can reduce late toxicity parameters, such as xerostomia, by 
increasing sparing of the parotid glands.40 However, it has 
several drawbacks such as complexity of treatment planning 
and delivery requiring extensive quality assurance, prolonged 
beam delivery time which may worsen the accuracy of treat-
ment because of increased intrafractional patient motion, and 
reduced patient throughput with subsequent longer waiting 
lists. Another issue of concern is the increased number 
of monitor units (MUs) required for IMRT, which could 
increase the number of secondary malignancies after curative 
treatment.41 In this context, VMAT represents a valid strat-
egy to overcome the above-cited IMRT drawbacks. Indeed, 
planning studies have reported that VMAT plan quality is at 
least comparable to standard IMRT, with shorter planning 
and delivery time, and less MUs.7,8,14,42
A few retrospective clinical studies have investigated 
the impact of VMAT in H&NC, totaling ~533 patients43–48 
(Table 2); also in this setting, the dual-arc-VMAT–SIB tech-
nique was the dosimetric treatment of choice. Prophylactic 
treatment of lymph nodes was performed with doses between 
40 Gy and 57.75 Gy according to different protocols, with 
fractionation ranging from 1.3 to 1.8 Gy per fraction. The 
visible disease documented by imaging and/or physical 
examination received doses up to 75 Gy, with dose fraction 
ranging between 2 and 2.4 Gy. Three of the 6 studies reported 
the use of IG (kV or MV) during delivery.43,44,47 A limitation 
present in all studies was the enrollment of mixed histo-
types, except for the Guo et al study that reported the largest 
VMAT–SIB nasopharyngeal carcinoma series (N=205).48 
Toxicities Grade 3 were confluent mucositis (range 
28%–49%), cutaneous moist desquamation (14%–38%), 
dysphagia (7%–63%), and pain requiring opioid analgesia 
(49%). Outcome data were provided by Scorsetti et al43 who T
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reported that clinical response to treatment was encourag-
ing, by Smet et al45 who reported survival data favoring 
VMAT compared to IMRT, and by Guo et al48 who reported 
a 36-month locoregional relapse-free survival of 94% and a 
36-month OS of 97.0% (Table 2).
In conclusion, preliminary results in locally advanced 
H&NC treated with VMAT showed acceptable or favorable 
toxicity profile48 even using concomitant chemotherapy. 
Duration of follow-up within the available studies is hetero-
geneous; moreover, in the only study providing a comparison 
between the 2 techniques, follow-up duration was shorter in 
patients managed with VMAT compared to IMRT.45 Pro-
spective trials with longer follow-up are needed to achieve 
reliable conclusions on this matter.
Thoracic neoplasm: exclusive and 
adjuvant settings
A few heterogeneous clinical studies have investigated the use 
of VMAT in thoracic neoplasm (Table 3);49–52 the rationale 
to use VMAT in this field sounds reasonable since the IMRT 
quality dose distributions can still be achieved, but in a shorter 
treatment time that could minimize the impact of intrafraction 
motion.53 Moreover, the convex hull lung tumor shape makes 
the delivery of VMAT advantageous and competitive with 
respect to conventional IMRT in terms of contralateral lung 
and spinal cord sparing. Concerns still remain regarding the 
increase of normal tissue volume receiving low-dose radia-
tion in addition to the potential increased risk of secondary 
malignancy induction especially for breast disease.53
Scorsetti et al49 reported acute toxicity, initial outcome 
results, and therapeutic planning parameters in radiation treat-
ment of advanced lung cancer (Stage III) with volumetric 
modulated arcs using RapidArc (RA). The earliest published 
study investigated the clinical outcome of 24 nonsmall cell lung 
cancer patients treated with VMAT: despite the large target 
volumes (gross tumor volume: 299±175 cm3, planning target 
volume: 818±206 cm3) and delivery of curative doses, no severe 
toxicity was recorded. Moreover, partial response and stabili-
zation of disease were documented in 78% and 22% of cases, 
respectively, thus highlighting the therapeutic potential of this 
strategy which nonetheless requires further investigations.49
Another field of application of VMAT in the thoracic area 
is represented by pleural mesothelioma whose treatment after 
extrapleural pneumonectomy can include adjuvant irradia-
tion.50 Based on the encouraging results obtained with adjuvant 
IMRT in terms of increased delivered doses and better local 
control compared to 3D-CRT technique, attention has been 
focused on the use of VMAT in the same clinical setting 
because of the possibility of reducing the contralateral lung 
dose volume receiving 5 Gy (V5), or the mean lung dose thus 
resulting in a lower rate of severe pulmonary toxicity. Indeed, 
only 1 study has addressed this issue reporting a rate of acute 
Grade 3 pneumonitis in 20% of patients, a figure that favorably 
matches with previously reported data on IMRT.54,55
The rationale of VMAT in breast cancer adjuvant treat-
ment concerns a specific subset of patients whose hearts 
are positioned close to the chest wall and who could not be 
adequately treated with a modified wide-tangent technique. 
In dosimetric studies, VMAT plans showed a statistically 
significant reduction in mean dose to the heart and ipsilat-
eral (left) lung compared with IMRT.56 A reduction in the 
volume of heart and lung receiving low doses (eg, 10 Gy 
and 5 Gy) may be important in the subgroup of patients who 
have received anthracycline-based chemotherapy and/or 
trastuzumab. The mean dose to the full contralateral breast 
was lower as well.56 Scorsetti et al reported the use of the 
3-week VMAT–SIB course as adjuvant treatment after 
breast-conserving surgery;57 their Phase II trial showed that 
the technique is well tolerated and associated with optimal 
local control.52
To our knowledge, 2 studies analyzed the role of VMAT 
in the exclusive as well as adjuvant setting.51,52 In particular, 
in the larger prospective series by De Rose et al, VMAT–
SIB (40.5 Gy on the whole breast, 48 Gy on surgical bed) 
provided a very favorable acute and late toxicity profile;52 
with the limits inherent in the relative short follow-up, an 
optimal 2-year local control rate was documented.
A different clinical setting was investigated by Kim et al 
who delivered up to 50 Gy to the whole breast and up to 
60–70 Gy on tumor sites.51 As far as toxicity is concerned, 
late Grade 2 was registered in only 3.2% of cases.
GU cancer: exclusive and adjuvant 
settings
The increasing incidence of prostate cancer (PC) and endo-
metrial cancer (EC), as well as the favorable rate of curability 
and long survival, justifies the strenuous pursuit of healthy 
tissue toxicity reduction policy.
Indeed, treatment of pelvic lymph nodes as well as the 
primary tumor or tumor bed is indicated in high-risk PC 
and EC patients by international guidelines [www.NCCN.
org]. The so-called horseshoe shape of the lymph node 
target, which includes the small intestine and rectum in its 
concavity, represents a condition particularly suitable to 
benefit from the intensity-modulated techniques and espe-
cially from VMAT.
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Concerning PC, dosimetric studies demonstrated a com-
parable or higher sparing to organs at risk (OARs) obtained 
with VMAT in comparison with the IMRT plans, especially 
by dual-arc technique that can obtain a superior conformity 
and homogeneity compared with single-arc plans.58–60 In 
addition, the better efficiency of VMAT delivery reduces the 
treatment time, making it an attractive solution for radiation 
oncologists.58–60
Eight clinical studies (5 prospective and 3 retrospec-
tive) have been reviewed in this study;61–68 PC represents 
the disease on which VMAT has been employed since the 
beginning and most frequently.
Five studies addressed only exclusive setting,62,64–67 
while the remaining studies investigated adjuvant setting63 
or both.61,68 Most of the patients enrolled in these studies 
(including series between 23 and 113 patients) were treated 
mostly by VMAT–SIB dual-arc and triple-arc techniques, 
almost all using IG as kilovoltage (kV) or cone-beam com-
puted tomography (CBCT). It is important to mention the 
importance of IG during RT, for example, with CBCT. This 
enables patient positioning errors to be followed and corrected 
with high precision. In PC, where internal organ movement is 
a key point for patient positioning and target localization,69 IG 
permits the safe delivery of higher doses per fraction. Pesce 
et al and Sveistrup et al treated only prostate volume, thus 
using single-arc technique up to 78 Gy/2 Gy fraction;61,65 both 
authors reported that IG-VMAT is a safe treatment for PC, 
with few and mild changes in urinary and GI symptoms after 
1 year from RT completion. Sexual symptoms deteriorated 
during and after RT; however, Pesce et al61 reported preserva-
tion of erectile function in 44% of patients, while Sveistrup 
et al65 stressed the issue that the use of hormonal therapy was 
associated with worse sexual symptoms. However, prostatic 
antigen decreased to values close to zero at the end of the 
treatment, thus leading consideration of clinical outcome as 
encouraging. No data on local control or OS are available.
To date, the study by Sveistrup et al65 is the one with the 
most comprehensive analysis of the symptoms before, dur-
ing, and after the RT; however, the limitation of this work 
is the use of a questionnaire (Prostate Cancer Symptom 
Scale – PCSS scale) which makes it difficult to compare data 
with other experiences.
Pelvic lymph nodes, prostate, and seminal vesicles were 
treated by 5 authors62,64,66–68 using a single- to triple-arc tech-
nique, with doses ranging from 46.8 Gy for nodal coverage 
to 78 Gy for prostate irradiation. Almost all used IG as kV 
or CBCT, and ~335 patients were treated from 2012 to 2016. 
The conclusions were that VMAT–SIB is technically feasible 
and safe providing high target coverage and OAR sparing 
with acceptable GI and GU toxicity. Hegazy et al reported 
that ~50% of patients (low and intermediate risk) with partial 
potency prior to RT retained functional potency on long-term 
follow-up (median 16 months; range: 14–32).67
Moreover, Hesselberg et al68 confirmed a favorable acute 
toxicity profile also in the case of treatment of large pelvic 
lymph node volumes with optimal dose coverage. Finally, Ng 
et al64 paid attention to a not trivial issue: as the population 
ages, the number of patients presenting with hip prostheses 
is expected to increase, and treatment planning for patients 
with metallic prosthesis composed of high Z materials posed 
challenges. In fact, hip prosthesis determines streaking and 
blurring artifacts in the CT data set which prevents accurate 
contour delineation and alters the image density values and 
moreover implies dose calculation uncertainties.70,71 In this 
context, Ng et al64 outlined that VMAT provides an elegant 
solution to deliver dose-escalated RT in patients with uni-
lateral and bilateral hip replacements with minimal acute 
and late toxicities. Only Hegazy et al reported outcome data 
reporting 2- and 3-year biochemical recurrence-free survival 
of 90% and 72%, respectively; the 3- and 4-year OS rates 
were 88% and 72%, respectively (Table 4).67
More recently, clinical data on EC have been reported by 
Alongi et al72 and Macchia et al73 in 2 Phase I–II studies enroll-
ing patients treated on pelvic lymph nodes and boosted on the 
vaginal cuff by VMAT–SIB dual-arc techniques. The 2-year 
local control rates were 98.5% and 100% in the 2 studies, with 
OS rates ranging from 94% and 96% (Table 4). Both authors 
concluded that VMAT is feasible and well tolerated in terms 
of acute as well as late toxicities. Indeed, while recognizing 
that vaginal brachytherapy represents the standard technique 
for vaginal vault irradiation (less dose to OAR, no organ 
motion, reduction of linear accelerator overload, and treatment 
time), the authors stated that VMAT–SIB not only represents 
a valid option in the case of lack of vaginal brachytherapy, but 
can be used in special conditions like unfavorable anatomy or 
patient refusal and/or claustrophobia.72,73 However, prolonged 
follow-up is needed to evaluate other clinical results includ-
ing late toxicity and local control and survival. Additional 
issues such as secondary malignancy induction should also 
be examined, given the paucity of data relative to this type 
of risk for IMRT and VMAT techniques.
Anorectal cancer: exclusive and 
neoadjuvant settings
Exclusive or neoadjuvant concomitant chemoradiation is 
presently considered as the standard treatment option for 
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patients with anorectal cancer, providing consistent rates of 
locoregional control (LC), sphincter preservation, and OS. 
The acute toxicity profile linked to this approach, especially 
if a multidrug regimen is coupled to chemoradiation, refers 
particularly to skin, GI, and GU OARs and may potentially 
hinder the dose escalation to tumor volume, or stop treatment 
for a prolonged period, thereby reducing the radiobiologi-
cal effectiveness of therapy.12,74 Seven clinical studies from 
2010 to 2016 reported data on rectal or anal cancers treated 
by VMAT (Table 5).75–81 The rationale, also in this setting, is 
closely related to the higher OAR sparing, dose escalation pos-
sibility, and faster delivery compared to 3D-CRT or IMRT.
In particular, in the neoadjuvant setting of rectal cancer 
(RC), 3 studies accounting for 124 patients were included.75–77 
Two of them, 1 prospective and 1 retrospective, compared 
VMAT technique to 3D-CRT with conventional doses 
(45/1.8 or 50.4/1.8 Gy).75,76 Richetti et al75 prospectively 
treated 25 RC patients by single arc, while Dröge et al76 
retrospectively studied ~81 patients treated by a dual-arc 
technique; both authors concluded that VMAT improves con-
formality and reduces treatment times, with similar treatment 
outcomes.75,76 Moreover, in the larger study,76 a reduction of 
the high-grade acute and late toxicities was documented. On 
the other hand, in a Phase II study with concurrent multidrug 
chemotherapy (oxaliplatin plus capecitabine), Picardi et al77 
first used the VMAT–SIB strategy to escalate doses on 
macroscopic disease up to 57.5 Gy (2.3 Gy/fraction), while 
delivering 45 Gy (1.8 Gy/fraction) to pelvic lymph nodes. 
The authors reported an excellent pathologic response rate 
(pT0-Tmic: 61.1%) with quite encouraging outcomes also 
in terms of local control, DFS, and OS (Table 5). However, 
despite the use of the VMAT technique, ~44% of patients 
had a non-negligible acute toxicity, hence they concluded 
that the implementation of IMRT and VMAT in RC is attrac-
tive and potentially facilitates dose escalation, but increases 
the risk of developing acute proctitis because the rectum 
inevitably receives high doses; therefore, the use of this 
scheme can be justified in clinical practice only in patients 
with advanced disease.
On the other hand, in the exclusive setting of anal cancer, 
4 chemoradiation studies (1 Phase I and 3 retrospective ones 
accounting for 103 patients) were analyzed.78–81 One of them80 
investigated the irradiation of a single volume with either 
2 full arcs or 4 half-arc VMAT technique and 6 MV photon 
energies. The delivered dose of 50.4 Gy at 1.8 per fraction 
caused mostly severe skin toxicity (29.4%), with low GI 
(11.8%) and GU (5.9%) severe toxicity. These figures are 
lower than the ones reported in 3D-CRT studies, for example, Al
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in Radiation Therapy Oncology Group 98-11 trial that 
reported a crude rate of acute Grade 3/Grade 4 toxicities of 
48% for the skin and 35% for GI.82 One of the major issues 
that should be clarified for VMAT is whether single or mul-
tiple arcs should be applied to realize proper treatments. In 
our review, 3 studies employed a dual-arc SIB approach78–81 
delivering a different daily dose to selected treatment vol-
umes during the same treatment fraction. According to dosi-
metric results by Clivio et al,12 the double arcs can slightly 
improve the sparing of OAR guaranteeing more flexibility in 
dose modulation compared to single-arc treatments.
In 3 studies,78–80 elective lymph nodes received doses 
between 45 and 49.5 Gy (1.5 Gy/fraction); clinically detect-
able lymph nodes were treated with doses from 50.4 to 54 Gy 
(1.8–2 Gy/fraction), and macroscopic anal disease received 
doses from 50.4 to 59.4 Gy (1.8 Gy/fraction). Noteworthy, the 
SIB approach was able to shorten the overall treatment time 
with a consequent potential benefit on treatment outcomes.
The study reporting the most frequent toxicity was that by 
Leon et al79 who documented the rates of skin and GI toxic-
ity in 63% and 36% of cases respectively, figures closer to 
3D-CRT values than IMRT/VMAT.82 Besides the limits of 
the sample size (N=11), it is conceivable that these results 
may be ascribed to the higher total dose and, more probably, 
to the highest dose per fraction (2.13 Gy) plus the addition 
of cetuximab that may have contributed to induce severe 
dermatitis given its peculiar skin toxicity properties. None of 
the other studies reported similar results, hence they cannot 
be justified given the poor clinical outcome (Table 5).
In conclusion, the available studies provided further 
lines of evidence supporting the implementation and use of 
VMAT–SIB on a routine basis for the treatment of cancer 
of the anal canal in combination with concurrent CT due to 
lower rates of acute organ toxicity and promising trends in 
LC and DFS.
SBRT–vMAT (exclusive setting)
In the “oligo-metastatic” setting, local approach may improve 
the outcome by keeping the burden of disease below the 
lethal threshold. However, most patients are unfit for surgery 
because of unfavorable tumor factors or poor general condi-
tions. For these patients, a broad variety of alternative local 
therapeutic approaches are available besides conventional 
radiochemotherapy approaches. SBRT is a high-precision 
technique with tight planning margins and a sophisticated 
treatment plan allowing rapid dose fall-off away from the 
treatment area. It provides improved volume targeting and 
smaller irradiated volumes of normal tissue. On the other Fr
an
co
 
et
 a
l81
A
nu
s
R
eX
C
C
R
T
39
v
M
A
T
–S
iB
 1
–2
 a
rc
s:
m
ac
ro
sc
op
ic
 d
is
ea
se
: 
50
.4
–5
4 
(1
.8
);
cl
in
ic
al
 ly
m
ph
 n
od
es
: 
50
.4
–5
4 
(1
.6
8–
1.
8)
; 
el
ec
tiv
e 
ly
m
ph
 
no
de
s:
 4
5 
(1
.5
)
C
BC
T
G
U
: 2
%
G
i: 
5%
Sk
in
: 1
8%
Le
uk
op
en
ia
: 3
2%
N
eu
tr
op
en
ia
: 3
1%
T
hr
om
bo
cy
to
pe
ni
a:
 
13
%
C
T
C
A
e
na
21
.5
 (
6–
50
)
na
24
 m
on
th
s 
co
lo
st
om
y‑
fr
ee
 
su
rv
iv
al
: 7
7.
9%
12
 m
on
th
s:
 
10
0%
24
 m
on
th
s:
 
84
.5
%
12
 m
on
th
s:
 
10
0%
24
 m
on
th
s:
 
85
.2
%
N
ot
es
: a
20
 in
 t
he
 c
om
pa
ri
so
n 
gr
ou
p 
of
 3
D
‑C
R
T
; b
10
7 
in
 t
he
 c
om
pa
ri
ng
 g
ro
up
 3
D
‑C
R
T
; c
28
 in
 t
he
 c
om
pa
ri
ng
 g
ro
up
 3
D
‑C
R
T
; d
86
 in
 t
he
 c
om
pa
ri
ng
 g
ro
up
 3
D
‑C
R
T
.
A
bb
re
vi
at
io
ns
: P
, p
ro
sp
ec
tiv
e 
st
ud
y;
 R
, r
et
ro
sp
ec
tiv
e 
st
ud
y;
 e
X
C
 C
R
T
, e
xc
lu
si
ve
 c
he
m
or
ad
ia
tio
n;
 H
e,
 h
em
at
ol
og
ic
; N
A
 C
R
T
, n
eo
ad
ju
va
nt
 c
on
cu
rr
en
t c
he
m
or
ad
ia
tio
n;
 P
D
, p
ro
gr
es
si
ve
 d
is
ea
se
; v
M
A
T
, v
ol
um
et
ri
c 
m
od
ul
at
ed
 a
rc
 th
er
ap
y;
 
Si
B,
 s
im
ul
ta
ne
ou
s 
in
te
gr
at
ed
 b
oo
st
; i
M
R
T
, i
nt
en
si
ty
‑m
od
ul
at
ed
 r
ad
io
th
er
ap
y;
 C
BC
T
, c
on
e‑
be
am
 C
T
; M
v
Pi
, m
eg
av
ol
ta
ge
 p
or
ta
l i
m
ag
in
g;
 F
U
P,
 fo
llo
w
‑u
p;
 G
i, 
ga
st
ro
in
te
st
in
al
; G
U
, g
en
ito
ur
in
ar
y;
 O
R
R
, o
ve
ra
ll 
re
sp
on
se
 r
at
e;
 C
R
, c
om
pl
et
e 
re
sp
on
se
; P
R
, p
ar
tia
l r
es
po
ns
e;
 L
R
, l
oc
al
 r
es
po
ns
e;
 T
R
, t
ot
al
 r
es
po
ns
e;
 L
C
, l
oc
al
 c
on
tr
ol
; D
FS
, d
is
ea
se
‑fr
ee
 s
ur
vi
va
l; 
O
S,
 o
ve
ra
ll 
su
rv
iv
al
; n
a,
 n
ot
 a
va
ila
bl
e;
 C
T
C
A
e,
 C
om
m
on
 T
er
m
in
ol
og
y 
C
ri
te
ri
a 
fo
r 
A
dv
er
se
 e
ve
nt
s 
sc
al
e;
 3
D
‑C
R
T
, t
hr
ee
‑
di
m
en
si
on
al
 c
on
fo
rm
al
 r
ad
io
th
er
ap
y.
OncoTargets and Therapy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3768
Macchia et al
hand, VMAT is recognized to increase delivery efficiency 
and reduce the risk of intrafraction deviations in terms of 
both setup errors and organ motion; therefore, VMAT may 
represent a valuable technique for SBRT treatment.
Little evidence exists concerning the feasibility of 
SBRT–VMAT in different clinical settings; Table 6 reports 
isolated experiences in radical treatment of metastases or 
primary tumors at various sites.83–88 Six studies (2 retrospec-
tive and 4 prospective Phase I–II trials) reported results 
on ~284 patients; in the majority of these studies, Image 
Guided by means of CBCT was used for daily treatment 
verification.83,85,87,88 A large variability of total dose and dose 
per fraction arose from the study analysis, probably due to 
the site of metastatic site as well as lack of literature about 
this issue. Of course, this variability limits any specific com-
parison, but it has to be recognized that the common denomi-
nator of the studies is the high rate of local control (range: 
72%–94.7%) and the low rate of acute toxicity recorded by the 
Common Terminology Criteria for Adverse Events scale.
A special consideration should tribute to the recent imple-
mentation of flattening filter-free (FFF) beams technology 
that increases the dose rate by removing flattening filter.89 
The basis of the use of FFF beams for delivering SBRT doses 
is the potential possibility to deliver very high doses faster 
and more precisely, with a strong impact on time factor and, 
therefore, on intrafraction motion and total session treatment 
time. The FFF technology has been applied in Scorsetti et al 
and Franceschini et al trials,87,88 with the authors concluding 
that, in clinical practice, it could be potentially translated into 
less toxicity and subsequently in a better quality of life.
Among the reported studies, the trial by Deodato et al86 
represents the only experience with stereotactic radiosurgery: 
with this technique, which is based on the delivery of a single 
high dose of radiation using high-precision technologies, 
favorable results in terms of response (95%) and LC (2-year 
LC =72%) were achieved with acceptable morbidity.
Similar findings were reported by Filippi et al90 who 
treated 90 lung lesions, of which 34 were managed by 
stereotactic radiosurgery; these results are not presented in 
Table 6 because it was not possible to retrieve the data about 
SBRT–VMAT from the whole series.
In conclusion, the possibility to easily integrate SBRT–
VMAT in the context of a systemic treatment due to intrinsic 
low toxicity and fast administration makes this approach very 
attractive. From a practical point of view, the introduction 
of VMAT for SBRT has resulted in a marked reduction 
of treatment time (especially by FFF beams technology), 
intrafraction uncertainties, costs related to highly complex T
ab
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treatment, and higher patient acceptance and compliance 
to treatment.
Discussion and conclusion
Few papers in literature evaluated systematically the clinical 
efficacy of VMAT technique in cancer treatment. In 2011, 
Teoh et al24 reviewed the current literature and clinical 
use in practice of VMAT treatment in various tumor sites 
including prostate, lower GI, gynecological, head and neck, 
thoracic, central nervous system, and breast. Obviously, due 
to the time frame, the study was extremely complete about 
dosimetric issues, while reporting few clinical data about 
clinical outcome. A recent paper by Infusino et al25 has been 
published, mainly focusing attention on the clinical utility of 
RapidArc™ technology.
This is the first clinical review about VMAT technique 
regardless of the manufacturing company, notwithstanding 
plenty of dosimetric studies on the latter.
The use of VMAT in radiation oncology has increased 
over the years, but its role on clinical outcome is still being 
explored; indeed, over a 7-year span, only 37 studies reported 
clinical results in terms of outcomes and toxicity. Interestingly, 
the majority of papers were prospective (N=21) reflecting the 
growing interest of the issue. However, published series 
appear inhomogeneous in terms of study design, setting of 
irradiation, doses, concomitant chemotherapy, and evaluation 
of outcomes and toxicities. Moreover, no randomized studies 
are available, and 17 out of 37 studies did not report any data 
on late toxicity, probably because of the short follow-up time. 
In addition, toxicities could have been underestimated since 
relative data were captured retrospectively.
We identified 6 major clinical scenarios for VMAT treat-
ments and were able to estimate local control and toxicity 
for all indications, albeit with the aforementioned limits 
including the context of retrospective single institutional 
studies and inherent biases associated with them. The major-
ity of studies report an excellent OAR sparing compared to 
IMRT; waiting for the setup of randomized clinical trials 
focused on this issue, VMAT can be considered a valid 
alternative option.
Based on the data collected in this review, PC treatment 
with VMAT has received the greatest support in the current 
literature, followed by anorectal cancer. In these settings, 
patients received mostly VMAT–SIB, thus being able to 
benefit from the SIB strategy that allows increasing of dose 
per fraction to the boost volume, keeping the elective volume 
dose at a lower level, and providing clinical and dosimetric 
advantages.
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For all series, the therapeutic results appear encouraging, 
especially when large volumes need to be irradiated, and 
dual-arc SIB strategy is used,77 or high-sensitive structure 
sparing is required.32
In conclusion, the literature addressing the clinical appro-
priateness of VMAT is scarce. Current literature suggests that 
VMAT, especially when used as SIB or SBRT strategy, is 
an effective safe modality for all cancer types. Prospective 
studies with systematic data collection are needed for further 
understanding of the VMAT role in daily clinical use.
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